Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 2

Status

Completed 5Withdrawn 1

Sponsor Class

OTHER 5

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Breast 4Gastrointestinal 1

Conditions

Breast Neoplasms 3Esophagogastric Cancer 1Breast Cancer Metastases 1

Interventions

Cyclophosphamide 1499Cisplatin 1435Paclitaxel 1340Radiotherapy 1310Carboplatin 1267Gemcitabine 1226Docetaxel 1133Bevacizumab 1070Fluorouracil 906Doxorubicin 805Dexamethasone 755Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 700Etoposide 679Irinotecan 639Filgrastim 624Cytarabine 587Nivolumab 586Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × zirconium-89-trastuzumab × Clear all
NCT01565200 2025-03-31

ZEPHIR

Jules Bordet Institute

Phase 2 Completed
90 enrolled
Breast

Breast Neoplasms

NCT02023996 2024-12-10

PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer

Memorial Sloan Kettering Cancer Center

Phase NA Completed
42 enrolled 11 charts
Gastrointestinal

Esophagogastric Cancer

NCT02286843 2021-06-18

Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?

Memorial Sloan Kettering Cancer Center

Phase NA Completed
49 enrolled 8 charts
Breast

Breast Cancer Metastases

NCT01832051 2015-11-05

Clinical Value of 89Zr-trastuzumab PET

University Medical Center Groningen

Phase 2 Completed
20 enrolled
Breast

Breast Neoplasms

NCT01081600 2013-05-14

AUY922

University Medical Center Groningen

Completed
7 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡